Biosimilar Antibodies are antibodies sharing identical active biological components with the original therapeutic antibodies, serving as positive controls for drug efficacy evaluation in scientific research and supporting functional validation of target proteins.
Valanafusp is a recombinant protein biosimilar expressed in CHO cells, targeting INSR, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Datopotamab is a monoclonal antibody biosimilar expressed in CHO cells, targeting TACSTD2, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Plamotamab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD3E/MS4A1, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Plamotamab (XmAb13676) is a tumor-targeted antibody that contains both a CD20 binding domain and a cytotoxic T-cell binding domain (CD3). An XmAb Bispecific Fc domain serves as the scaffold for these two antigen binding domains and confers long circulating half-life, stability and ease of manufacture on plamotamab. CD20 is highly expressed on B-cell tumor cells, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) cells. Engagement of CD3 by plamotamab activates T cells for highly potent and targeted killing of CD20-expressing tumor cells. The structural stability and modularity enabled by the XmAb Bispecific Fc domain allowed the tuning of plamotamab’s potency to balance anti-tumor activity with the reduction of immune toxicity that can result from T-cell activation.
Abx-Ma1/c3.19.1 is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD146/MUC18, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. c3. 19. 1refers to a fully human IgG2 monoclonal antibody directed against the MUC18 antigen. The antibody consists of human gamma 2 heavy and kappa light chains with a molecular weight of approximately 150 kDa.
Tebotelimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting PDCD1/LAG3, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Bispecific scFv, IgG4, Kappa, Kappa.
Bavituximab is a monoclonal antibody biosimilar expressed in CHO cells, targeting Phosphatidylserine, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Bavituximab is a chimeric Anti-PS monoclonal antibody analog which is used to potentially treat cancers and viral infections. It binds to phosphatidylserine and other exposed host cell lipids when induced by cellular stress. Additional analogs in the class include 3G4, 2aG4, 9d2 and Hu3g4. Bavituximab Anti-Cancer is a monoclonal antibody that binds to a basic component of the cell structure called a phospholipid that is exposed only on the surface of tumor blood vessel cells or on cells infected with certain viruses. Bavituximab binding to the tumor blood vessel cells alerts the body’s immune system to attack the tumor and its blood supply. This has been shown to inhibit tumor growth and development. Because in healthy cells the phospholipids are concealed inside the cell, the bavituximab does not bind to them. This targets the bavituximab to the malignant cells and potentially minimizes unwanted side effects.
Alnuctamab is a monoclonal antibody biosimilar expressed in CHO cells, targeting TNFRSF17/CD3E, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Bispecific, IgG1, IgG1 Kappa, Lambda.
This product is for research use only (RUO) by laboratories. It is not suitable for use in humans or as a medicine. Vepsitamab is a Chimeric Humanized Monoclonal antibody targeting MUC-3, expressed in Mammalian cells.
Brolucizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting VEGFA, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Brolucizumab, also known as RTH258 or ESBA1008, 4 is a monoclonal antibody indicated to treat neovascular age related macular degeneration. Brolucizumab was granted FDA approval in October 2019. 6.
Ongericimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting PCSK9, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Suppliers
Request a product
Please provide the required information below so that we can quickly source your products.
